Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
February 12, 2021
Revance to Release Fourth Quarter and Full Year 2020 Financial Results on Monday, February 22, 2021
January 25, 2021
Revance to Highlight Aesthetic Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Filler Study Results at Maui Derm for Dermatologists 2021
January 22, 2021
Revance Issues Inaugural Environmental, Social and Governance (ESG) Report
January 19, 2021
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 7, 2021
Revance to Participate in the 39th Annual J.P. Morgan Healthcare Conference
January 7, 2021
Revance Provides Corporate Update and Anticipated Milestones for 2021
December 22, 2020
Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection
December 21, 2020
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 17, 2020
Revance Reports Positive Efficacy and Duration Results from Phase 2 Upper Facial Lines Study
November 25, 2020
FDA Defers Approval of DaxibotulinumtoxinA for Injection in Glabellar Lines Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspection
Displaying 41 - 50 of 277